{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:30:58Z","timestamp":1792679458309,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,10,30]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB). However, clinical trials to evaluate the efficacy of preventive therapy for presumed multidrug-resistant (MDR) LTBI are lacking. This trial aims to evaluate the efficacy of the antibiotic levofloxacin in preventing the development of active TB among latently infected contacts of index patients with MDR-TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A double-blind placebo-controlled parallel group randomised controlled trial will be conducted in 10 provinces of Vietnam. Household contacts living with patients with bacteriologically confirmed rifampicin-resistant or MDR-TB will be eligible for recruitment if they have a positive tuberculin skin test or are known to be immunosuppressed, and do not have active TB. Participants will be randomised to receive either levofloxacin or placebo tablets once per day for 6\u2009months. Screening for incident TB will be performed at 6\u2009months intervals. The primary study outcome is the incidence of bacteriologically confirmed TB within 30 months after randomisation. Analysis will be by intention to treat, using Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics<\/jats:title>\n                    <jats:p>Ethical approval from the University of Sydney Human Research Ethics Committee was obtained on 29 April 2015 (2014\/929), and from the Vietnam Ministry of Health Institutional Review Board on 30 September 2015 (4040\/QD-BYT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Dissemination<\/jats:title>\n                    <jats:p>Findings of the study will be published in peer-reviewed publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12616000215426.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-033945","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T18:28:02Z","timestamp":1578421682000},"page":"e033945","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1411","authenticated-orcid":false,"given":"Greg J","family":"Fox","sequence":"first","affiliation":[{"name":"Central Clinical School, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"},{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam Binh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Thuy","family":"Tran","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J","family":"Marais","sequence":"additional","affiliation":[{"name":"The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"},{"name":"The University of Sydney Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve M","family":"Graham","sequence":"additional","affiliation":[{"name":"Murdoch Childrens Research Institute, Parkville, Victoria, Australia"},{"name":"Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Hoa","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The National Lung Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavi","family":"Velen","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"},{"name":"The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Dowdy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, John Hopkins Bloomberg, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mason","sequence":"additional","affiliation":[{"name":"Taronga Institute of Science and Learning, Taronga Conservation Society, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick J","family":"Britton","sequence":"additional","affiliation":[{"name":"The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"},{"name":"Tuberculosis Research Program, The Centenary Institute of Cancer Medicine and Cell Biology, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel A","family":"Behr","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"McGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Departments of Medicine and of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[{"name":"McGill International Tuberculosis Centre, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet Nhung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The National Lung Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy B","family":"Marks","sequence":"additional","affiliation":[{"name":"Woolcock Institute of Medical Research, Glebe, New South Wales, Australia"},{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"2025121411382879000_10.1.e033945.1","unstructured":"World Health Organization . 2018 global tuberculosis report. 2018. Geneva, Switzerland: WHO, 2018."},{"key":"2025121411382879000_10.1.e033945.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"2025121411382879000_10.1.e033945.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30307-X"},{"key":"2025121411382879000_10.1.e033945.4","unstructured":"European Centre for Disease Prevention and Control . Management of contacts of MDR TB and XDR TB patients. Stockholm ECDC, 2012."},{"key":"2025121411382879000_10.1.e033945.5","unstructured":"The Stop TB Partnership . The global plan to stop TB 2011\u20132015. Geneva, 2010."},{"key":"2025121411382879000_10.1.e033945.6","unstructured":"Medecins Sans Frontiers . An evaluation of drug-resistant TB treatment scale-up. Geneva, 2011."},{"key":"2025121411382879000_10.1.e033945.7","unstructured":"World Health Organization . Latent tuberculosis infection. updated and consolidated guidelines for programmatic management. Geneva: WHO, 2018."},{"key":"2025121411382879000_10.1.e033945.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"2025121411382879000_10.1.e033945.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"2025121411382879000_10.1.e033945.10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/fmb-2017-0236","article-title":"Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis","volume":"13","author":"Byrne","year":"2018","journal-title":"Future Microbiol"},{"key":"2025121411382879000_10.1.e033945.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0069OC"},{"key":"2025121411382879000_10.1.e033945.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.08.024"},{"key":"2025121411382879000_10.1.e033945.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit655"},{"key":"2025121411382879000_10.1.e033945.14","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0028"},{"key":"2025121411382879000_10.1.e033945.15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025121411382879000_10.1.e033945.16","unstructured":"World Health Organization . WHO consolidated guideilnes on drug-resistant tuberculosis treatment. Geneva, Switzerland: WHO, 2019."},{"key":"2025121411382879000_10.1.e033945.17","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262140-00013"},{"key":"2025121411382879000_10.1.e033945.18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ156"},{"key":"2025121411382879000_10.1.e033945.19","doi-asserted-by":"crossref","unstructured":"Fair E , Miller C , Ottmani S , et al . Tuberculosis contact investigation in low and middle income countries: standardized definitions and indicators. Int J Tuberc Lung Dis. In Press 2015.","DOI":"10.5588\/ijtld.14.0512"},{"key":"2025121411382879000_10.1.e033945.20","unstructured":"Second Edition of Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide. Boston: The Sentinel Project for Pediatric Drug Resistant Tuberculosis, 2014."},{"key":"2025121411382879000_10.1.e033945.21","unstructured":"United States Food and Drug Administration (US FDA) . Levaquin (levofloxacin) tablets, oral solution and injection, 2014. Available: http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/ucm303865.htm [Accessed 20 June 2015]."},{"key":"2025121411382879000_10.1.e033945.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70071-9"},{"key":"2025121411382879000_10.1.e033945.23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00070812"},{"key":"2025121411382879000_10.1.e033945.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01751.x"},{"key":"2025121411382879000_10.1.e033945.25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5365\/wpsar.2016.7.2.002","article-title":"Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011","volume":"7","author":"Nguyen","year":"2016","journal-title":"Western Pac Surveill Response J"},{"key":"2025121411382879000_10.1.e033945.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700209"},{"key":"2025121411382879000_10.1.e033945.27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.aje.a121625","article-title":"Sample size requirements in cohort and case-control studies of disease","volume":"99","author":"Schlesselman","year":"1974","journal-title":"Am J Epidemiol"},{"key":"2025121411382879000_10.1.e033945.28","unstructured":"International Committee of medical Journal editors recommendations: defining the role of authors and contributors. Available: http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html [Accessed 21 Sept 2019]."},{"key":"2025121411382879000_10.1.e033945.29","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0609"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-033945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:38:38Z","timestamp":1765741118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-033945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,2]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bmjopen-2019-033945"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-033945","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}